Jul 2019 $10 M No. 5 $10 to $50 million 10
BioClin Therapeutics, Inc.: Raise no. 5, Jul 2019 × Investors in this round 10 investors had bought by the notice of Jul 26, 2019: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $19 M offered; $9 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Graeme M. Currie · Executive Officer · Chief Operating Officer Julie M. Eastland · Executive Officer · Chief Financial Officer and Chief Business Officer Scott D. Myers · Executive Officer, Director · Chairman, President, and Chief Executive Officer Steve M. Abella · Executive Officer · Chief Medical Officer Christian L. Richard · Director David L. Kabakoff · Director Fouad L. Azzam · Director Joel L. Jean-Mairet · Director Joseph L. Turner · Director Marten L. Steen · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Offer and Sale of Convertible Promissory Notes and the shares issuable thereunder”Signed by Max Barker, VP, Legal Affairs. Newest notice filed Jul 26, 2019. Read the notice at the SEC .
equity, debt SEC Jan 2019 $10 M No. 4 $10 to $50 million 10
BioClin Therapeutics, Inc.: Raise no. 4, Jan 2019 × Investors in this round 10 investors had bought by the notice of Feb 12, 2019: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $20 M offered; $10 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Graeme M. Currie · Executive Officer · Chief Operating Officer Julie M. Eastland · Executive Officer · Chief Financial Officer and Chief Business Officer Scott D. Myers · Executive Officer, Director · Chairman, President, and Chief Executive Officer Steve M. Abella · Executive Officer · Chief Medical Officer Christian L. Richard · Director David L. Kabakoff · Director Fouad L. Azzam · Director Joel L. Jean-Mairet · Director Joseph L. Turner · Director Marten L. Steen · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Offer and Sale of Convertible Promissory Notes and the shares issuable thereunder”Signed by Max Barker, VP, Legal Affairs. Newest notice filed Feb 12, 2019. Read the notice at the SEC .
equity, debt SEC Mar 2017 $50 M No. 3 $50 to $250 million 9
BioClin Therapeutics, Inc.: Raise no. 3, Mar 2017 × Investors in this round 9 investors had bought by the notice of May 14, 2018: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $50 M of $50 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Graeme L. Currie · Executive Officer · Chief Operating Officer Stephen W. Lau · Executive Officer, Director · President, Chief Executive Officer, and Treasurer Steve L. Abella · Executive Officer · Chief Medical Officer Christian L. Richard · Director David L. Kabakoff · Director Fouad L. Azzam · Director Joel L. Jean-Mairet · Director Joseph L. Turner · Director Marten L. Steen · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Offer and Sale of Series B Preferred Stock (and the shares issuable thereunder) and Special Voting Series B Preferred”Signed by Stephen W. Lau, President & CEO. Newest notice filed May 14, 2018 (1 amendment). Read the notice at the SEC .
equity SEC Apr 2014 $6 M No. 2 $2 to $10 million 1
BioClin Therapeutics, Inc.: Raise no. 2, Apr 2014 × Investors in this round 1 investor had bought by the notice of Apr 17, 2014: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eric L. Yuen · Executive Officer Kenneth L. Schwartz · Executive Officer Stephen Lau · Executive Officer, Director Jack L. Nielsen · Director Joseph L. Turner · Director Martin L. Steen · Director Peter L. Moldt · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Stephen Lau, Chief Executive Officer. Newest notice filed Apr 17, 2014. Read the notice at the SEC .
options SEC Dec 2012 $10 M No. 1 $2 to $10 million 1
BioClin Therapeutics, Inc.: Raise no. 1, Dec 2012 × Investors in this round 1 investor had bought by the notice of Jun 4, 2014: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Stephen Lau · Executive Officer, Director Joseph L. Turner · Director Thomas L. Boone · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Stephen Lau, Chief Executive Officer. Newest notice filed Jun 4, 2014. Read the notice at the SEC .
equity SEC